Sutro Biopharma, Inc. (STRO)
| Market Cap | 355.50M +388.9% |
| Revenue (ttm) | 45.70M -56.3% |
| Net Income | -180.64M |
| EPS | -15.47 |
| Shares Out | 16.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 108,233 |
| Open | 20.75 |
| Previous Close | 20.49 |
| Day's Range | 20.75 - 21.82 |
| 52-Week Range | 7.15 - 43.85 |
| Beta | 1.51 |
| Analysts | Strong Buy |
| Price Target | 47.23 (+120.29%) |
| Earnings Date | Aug 12, 2026 |
About STRO
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcin... [Read more]
Financial Performance
In 2025, Sutro Biopharma's revenue was $102.48 million, an increase of 65.18% compared to the previous year's $62.04 million. Losses were -$191.09 million, -15.99% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for STRO stock is "Strong Buy." The 12-month stock price target is $47.23, which is an increase of 120.29% from the latest price.
News
Sutro Biopharma reports Q2 EPS ($2.33), consensus ($2.27)
Reports Q2 revenue $9.84M, consensus $11.04M. “During the second quarter, we continued to execute swiftly across our next-generation ADC portfolio, highlighted by encouraging early clinical data from ...
H.C. Wainwright calls Sutro drop ‘an overreaction’ to limited STRO-004 data
H.C. Wainwright believes Sutro Biopharma’s (STRO) shares are trading lower largely on an overreaction to the limited efficacy disclosure for STRO-004. The firm thinks investors were looking for a more...
Sutro Biopharma price target lowered to $34 from $41 at Citizens
Citizens lowered the firm’s price target on Sutro Biopharma (STRO) to $34 from $41 and keeps an Outperform rating on the shares following the Q2 results and initial STRO-004 clinical…
Sutro Biopharma Slides: Corporate presentation
Sutro Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
– Encouraging early clinical activity i ncluding confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study –...
Sutro Biopharma Earnings release: Q2 2026
Sutro Biopharma released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Sutro Biopharma Quarterly report: Q2 2026
Sutro Biopharma has published its Q2 2026 quarterly earnings report on August 12, 2026.
Sutro Biopharma initiated with a Buy at Stifel
Stifel analyst Laura Prendergast initiated coverage of Sutro Biopharma (STRO) with a Buy rating and $48 price target The antibody-drug conjugates space is rapidly growing with about $20B in combined…
Sutro Biopharma assumed with a Buy at Truist
Truist assumed coverage of Sutro Biopharma (STRO) with a Buy rating and $50 price target The company’s refreshed ADC platform is increasingly compelling with multiple opportunities to generate proof-o...
Sutro Biopharma Transcript: AGM 2026
The meeting covered board elections, ratified the accounting firm, and approved executive compensation. The CEO emphasized accelerated clinical goals, and all proposals passed with a quorum present. No shareholder questions were raised.
Sutro Biopharma Transcript: Jefferies Global Healthcare Conference 2026
The company is accelerating its pipeline, with three ADC programs advancing to the clinic and a lead tissue factor ADC showing promising safety and efficacy in early trials. Rapid dose escalation and broad tumor representation set the stage for a midyear data readout, supported by strong preclinical data and a recent $110 million raise.
Sutro Biopharma initiated with an Overweight at Barclays
Barclays initiated coverage of Sutro Biopharma (STRO) with an Overweight rating and $56 price target Sutro is a a biopharmaceutical company focused on the development of antibody-drug conjugates for t...
Sutro Biopharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
STRO-004, a novel ADC with an exatecan payload, is advancing rapidly in phase I trials targeting multiple solid tumors. Preclinical and early clinical data suggest a wider therapeutic window and reduced toxicity compared to existing therapies, with initial results expected mid-year.
Sutro Biopharma price target raised to $10 from $9 at BofA
BofA raised the firm’s price target on Sutro Biopharma (STRO) to $10 from $9 and keeps an Underperform rating on the shares. The firm updated its model for Q1 results,…
Wedbush upgrades Sutro Biopharma to Outperform, raises price target to $60
As previously reported, Wedbush upgraded Sutro Biopharma (STRO) to Outperform from Neutral with a price target of $60, up from $22, after the company reported Q1 earnings and reiterated key…
Sutro Biopharma upgraded to Outperform from Neutral at Wedbush
Wedbush upgraded Sutro Biopharma (STRO) to Outperform from Neutral with a price target of $60, up from $22.
Sutro Biopharma price target raised to $50 from $28 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Sutro Biopharma (STRO) to $50 from $28 and keeps a Buy rating on the shares. The firm believes STRO-004…
Sutro Biopharma price target raised to $43 from $38 at Leerink
Leerink raised the firm’s price target on Sutro Biopharma (STRO) to $43 from $38 and keeps an Outperform rating on the shares.
Sutro Biopharma reports Q1 EPS ($2.94), consensus ($3.21)
Reports Q1 revenue $14.52M, consensus $7.41M. “During the first quarter, we continued to execute across our clinical and preclinical portfolio, positioning Sutro for key data readouts later this year,...
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued advancement of wholly-ow...
Sutro Biopharma Earnings release: Q1 2026
Sutro Biopharma released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Sutro Biopharma Quarterly report: Q1 2026
Sutro Biopharma has published its Q1 2026 quarterly earnings report on May 14, 2026.
Sutro Biopharma Slides: Corporate presentation
Sutro Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Sutro Biopharma initiated with an Outperform at Mizuho
Mizuho initiated coverage of Sutro Biopharma (STRO) with an Outperform rating and $50 price target The firm believes the company’s antibody-drug conjugate pipeline is positioned to reproduce a proven ...
Sutro Biopharma price target raised to $41 from $35 at Citizens
Citizens raised the firm’s price target on Sutro Biopharma (STRO) to $41 from $35 and keeps an Outperform rating on the shares. Recent AACR presentations highlighted strong preclinical results across…